EN

KO EN

Chat on Kakao

Business Inquiry

Our Solutions

About Us

Company Info

About Us

Corporate Name

BIO-FD&C Co., Ltd.

Founded

November 2005

Business Areas

  • R&D on physiologically active recombinant proteins
  • R&D on biomimetic peptides
  • R&D on plant callus (stem cell) extracts
  • R&D on traditional herbal extracts
  • Cosmetics OEM/ODM

Location

Medicinal Nanomaterial Institute 106, Sandan-gil, Hwasun-eup, Hwasun-gun, Jeollanam-do, S.Korea

GMP Certified Facility 98, Sandan-gil, Hwasun-eup, Hwasun-gun, Jeollanam-do, S.Korea

CEO Message

CEO Message

BIO-FD&C Co., Ltd. Medical Nano-material Research Institute stands at the forefront of global excellence in the research and development of biological formulations aimed at enhancing skin health.

Our commitment to innovation is demonstrated through our leadership in the domestic market for cosmetic and industrial raw materials, leveraging state-of-the-art biotechnologies, biological sciences, and plant tissue culture techniques. Our expertise spans a diverse array of materials, from proteins and peptides to natural substances and stem cell components.

Our consistent delivery of superior research outcomes has not only garnered multiple selections for prestigious national projects but has also established our position as Korea’s premier developer of cosmetic ingredients and bioactive industrial materials.

We are committed to upholding our reputation as a leading biotechnology entity and research institute. We extend our heartfelt thanks to our share holders and employees for their unwavering dedication and hard work.

Jung Dai Hyun , Mo Sang Hyun, Co-CEO

History

History of BIO-FD&C

2025

  • 11 Designated as Star Company by Hwasun-gun, Jeollanam-do.
  • 04 Won TOP 3 Global Media Pick Award at ICPI WEEK
  • 04 Acquired Chinese NMPA Approval for Micro-Needle Patch.

2024

  • 10 Acquired Medical Device Manufacturing License.
  • 07 Signed MOU with ECI, an Indian Aesthetic Medicine Specialist.
  • 05 Acquired ISO 13485 Certification.
  • 05 Signed Joint R&D and Commercialization Agreement for Medical Cannabis with Gencore.
  • 01 Signed MOU with the Natural Resources Research Center (JBF), Jeonnam Bioindustry Foundation.

2023

  • 12 Selected as Excellent Job Creation Company by Jeollanam-do.
  • 11 Awarded Digital Innovation Grand Prize (BT Sector).
  • 04 Signed MOU with Jeonbuk Branch of Korea Research Institute of Bioscience and Biotechnology (KRIBB).
  • 01 Honored with the IR52 Jang Young-Shil Award (No. 22-05922).

2022

  • 11 Acquired MFDS Approval for Porphyra 334 Functional Cosmetic.
  • 10 Signed MOU with MetaLab for Plant Cell Metaverse Content Development.
  • 09 Signed MOU with Latbio for Joint R&D of New Materials.
  • 08 Signed MOU with Cerenotics for Joint Development of Antibody Candidates.
  • 07 Signed MOU with ENCell for Joint R&D and Commercialization of Porphyra 334.
  • 03 Signed MOU with Y-Biologics for Mutual R&D Exchange and Cooperation.
  • 02 Listed on KOSDAQ
  • 01 Awarded Proud Korean Grand Prize (Bio Industry Sector) (No. 2022-4).

2021

  • 12 Submitted Securities Registration Statement.
  • 12 Received Preliminary Approval for KOSDAQ Listing.
  • 11 Signed CRISPR Gene Editing Technology Transfer and Mutual Cooperation Agreement with ToolGen.
  • 08 Passed Technology Evaluation (A_KED, BBB_NICE P&I), Lead Underwriter: DB Financial Investment.
  • 06 Published Paper in International Journal of Molecular Sciences.
  • 05 Selected as Global Hidden Champion by Ministry of SMEs and Startups.
  • 05 Received Minister's Award from Ministry of Science and ICT.
  • 04 Signed MOU with Medytox on Plant-Derived Growth Factor Technology.
  • 04 Registered Copyright for Rose GEM (Rose Virtual Cell) Construction Program (No. C-2021-016140) and Target Prediction Plant Virtual Cell Simulator (No. C-2021-016139).
  • 01 Signed Joint Research Agreement with Sungkyunkwan University for Ginseng GEM (Virtual Cell) Model.

2020

  • 10 Signed Joint Research and Cooperation Agreement with National Baekdudaegan Arboretum.

2019

  • 03 Secured Foreign Investment from GIVAUDAN (France).

2018

  • 08 Received Commendation from the Prime Minister.
  • 03 Designated as Global IP Star Company (Mar 2018 ~ Feb 2021).

2017

  • 10 Selected as K-Brain Power (Excellent Brain Competency Company).

2016

  • 08 Genome Sequencing of Rosa damascena and Registration on GenBank (GenBank: LYNE00000000.1).
  • 07 U.S. Patent Registration for Plant Cell Culture Technology using High-Frequency Device.
  • 07 Dispatched researcher to Arctic Dasan Station for Development of Utility Material Application Technology through circumpolar permafrost analysis.
  • 05 Gwangju/Jeonnam Office Factory Registration (Biological Products Manufacturing).
  • 03 New Construction and Relocation of Gwangju/Jeonnam Factory and Medical Nano-Material Research Institute.
  • 01 Incheon Factory Expansion.

2015

  • 10 Added Cosmetics Manufacturing Registration for Incheon Office.
  • 09 Secured Foreign Investment ($2.4 million) from SELECT RANGE LIMITED.
  • 02 Gwangju/Jeonnam Office Cosmetics Manufacturing Registration (No. 1859).
  • 01 Factory Expansion at Incheon and Gwangju/Jeonnam Offices.

2014

  • 12 Full-scale Export Launch to China, USA, Japan, and India.
  • 06 Gwangju/Jeonnam Office Designated as Promising SME (Technology-Promising) by Jeollanam-do (No. 2014-142(promising technology)).
  • 02 Incheon Office Factory Registration (Natural Resin and Wood Chemical Manufacturing).

2013

  • 05 Acquired LMO Research Facility Setup and Operation Permit (Safety Grade 1, No. LMOL13-144).
  • 03 Expanded and Relocated Incheon Headquarters and Anti-Aging Research Institute to Songdo.

2012

  • 07 Gwangju/Jeonnam Office Factory Registration (Biological Products Manufacturing).

2011

  • 11 Acquired Vision Company Certification from Incheon Metropolitan City (No. 2011-146).
  • 05 Selected as IP-STAR Company by the Korean Intellectual Property Office (KIPO).
  • 04 Established Anti-Aging Research Institute as a Corporate R&D Center at Incheon HQ.
  • 04 Established and Registered Gwangju/Jeonnam Branch of BIO-FD&C Co., Ltd.

2010

  • 12 Selected as Excellent R&D Project Group by Jeollanam-do.
  • 08 Discovered new gene, beta-defensin 3 homolog, related to ATOPY and registered on GenBank (GenBank : EU918408.1).
  • 07 Selected as Incheon High-Tech Promising Company (Incheon).
  • 01 Launched ATOVAX cosmetic product for Atopy improvement.

2009

  • 12 Selected as IP-WBC Company by KIPO.
  • 10 Acquired ISO 14001 Environmental Management System Certification (Environment management certification).
  • 01 Acquired INNO-BIZ (Technology Innovative SME) Certification (Level A).

2008

  • 10 Signed Industry-Industry MOU with ABLE C&C for New Material Research and Brand Development.
  • 09 Discovered and registered a new gene, beta-defensin 3 homolog, related to ATOPY in Gene Bank.
  • 09 Signed Trilateral Cooperation MOU with KAMEDIS (Israel) and Jeollanam-do on Joint R&D Investment.
  • 08 Acquired ISO 9001 Quality Management System Certification (Quality management certification).
  • 04 Relocated and Expanded Medical Nano-Material Research Institute (Corporate R&D Center) to Hwasun, Jeollanam-do.

2007

  • 11 Headquarters Expanded within Jeonnam Biomedical Research Center (JBRC).
  • 10 Corporate R&D Center Expanded and Relocated (JBRC).

2006

  • 12 Acquired Venture Company Certification.
  • 04 Established Skin Biosciences Research Institute (Corporate R&D Center).
  • 03 Capital Increase (Capital: KRW 900 million).

2005

  • 11 BIO-FD&C Co., Ltd. Founded.

Privacy policy

Through the privacy policy, the company informs you of the purpose and method of use of the personal information you provide, and what measures are being taken to protect your personal information.

▶ Purpose of collection and use of personal information

- Self-identification, real name verification, confirmation of subscription intent, use of age
- restricted services according to service use
- Contract performance regarding service provision and fee settlement, content provision, purchase and fee payment, product delivery or sending of invoices, etc.
- Delivery of notices, securing communication channels for complaint handling, securing accurate delivery information when delivering products
- Information for providing the latest information such as new services and providing personalized services
- Other smooth provision of high-quality services, etc.

▶ Items of personal information collected

- Name, company name, email, address, contact information, mobile phone number, inquiry content, and other optional items

▶ Retention and use period of personal information

- In principle, personal information is destroyed without delay upon achieving the purpose of collection or provision.
- However, in order to provide smooth service consultation, the contents may be retained for 3 months after the consultation is completed, and in cases where preservation is required by other laws such as the Act on Consumer Protection in Electronic Commerce, the information will be retained for a certain period of time.

▶ Personal information destruction procedures and methods

In principle, the company destroys the relevant information without delay after the purpose of collecting and using personal information has been achieved. The information you entered for membership registration, etc. is transferred to a separate DB (separate file in the case of paper) after the purpose has been achieved, and stored for a certain period of time according to internal policies and other relevant laws and regulations for information protection reasons (see retention and use period) and then destroyed. Personal information transferred to a separate DB will not be used for any other purpose than that for which it is retained, unless required by law. Personal information stored in electronic file format is deleted using a technical method that makes it impossible to reproduce the record.